Markets

Markets Overview Market Context

Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Market Context Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Live News EARNINGS FLASH H impact Oct 07, 2026, 11:11 AM UTC

Canada's Kits Eyecare preliminary Q3 beats estimates on glasses growth

(

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

KITS.TO

Related stories

US Stocks Pull Back from Records US stock indices eased from record highs as higher bond yields rebounded and hampered the earnings projections on debt-sensitive sectors. The S&P 500 and the Nasdaq 100 fell 0.5% a H impact | EARNINGS | Oct 07, 2026, 01:36 PM UTC Lucas GC Limited reports 1H 2026 financial results Lucas GC Limited (LGCL) reported 1H 2026 financial results, stating revenue of US$35.74 million and an increase in gross margin. M impact | EARNINGS | Oct 07, 2026, 01:01 PM UTC Qatar-Backed Carrier Airlink Sees ‘Ambitious’ Revenue Growth SA Airlink Pty Ltd., a South African carrier backed by Qatar Airways, expects a substantial increase in revenue this fiscal year as new deliveries of Embraer SA jets enable its exp L impact | EARNINGS | Oct 07, 2026, 12:24 PM UTC Maia Biotech completes Phase 2 enrollment for THIO-101 ateganosine plus cemiplimab Maia Biotechnology said Phase 2 enrollment is complete for the ateganosine plus cemiplimab cohort in THIO-101, with THIO-104 Phase 3 enrollment at 65% of a 100-patient year-end goa H impact | EARNINGS | Oct 07, 2026, 12:15 PM UTC Safe Pro Group stock jumps as Q3 revenue seen surging more than 2,300% L impact | EARNINGS | Oct 07, 2026, 12:14 PM UTC Cerevance reports positive Phase 3 Arise results for once-daily solengepras in Parkinson's 61 hours vs placebo at week 12, and showed motor and non-motor benefits; adverse-event discontinuation was 3.5%, same as placebo. M impact | EARNINGS | Oct 07, 2026, 12:10 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.